Oncolytic Immunotherapy: Where Are We Clinically?
Following a century of preclinical and clinical work, oncolytic viruses are now proving themselves in randomized phase 3 trials. Interestingly, human data indicates that these agents have potent immunostimulatory activity, raising the possibility that the key consequence of oncolysis might be induct...
Saved in:
Main Author: | Akseli Hemminki |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2014-01-01
|
Series: | Scientifica |
Online Access: | http://dx.doi.org/10.1155/2014/862925 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Oncolytic immunotherapy: multiple mechanisms of oncolytic peptides to confer anticancer immunity
by: Xing Huang, et al.
Published: (2022-07-01) -
The Clusmy Child: Where Are We and Where Are We Going?
by: Mijna Hadders-Algra, et al.
Published: (2003-01-01) -
Robotic Radical Cystectomy: Where are We Today, Where will We be Tomorrow?
by: Kyle A. Richards, et al.
Published: (2010-01-01) -
Predictive Biomarkers of Bacillus Calmette-Guérin Immunotherapy Response in Bladder Cancer: Where Are We Now?
by: Luís Lima, et al.
Published: (2012-01-01) -
Scoping review of brucellosis in Cameroon: Where do we stand, and where are we going?
by: Christopher G Laine, et al.
Published: (2020-01-01)